- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega. We discussed CMS's recent Medicare Part D and Medicare Advantage final rule and how it affects enrollees and health plans.
The final rule includes various measures, such as the requirements for health equity analysis and behavioral health provider inclusion. It also prioritizes access to accurate information for Medicare enrollees, mandates evidence-based supplemental benefits, and promotes biosimilar substitution.
Listen above or on one of these podcast services:
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
